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Abstract The main source of cholesterol in the central
nervous system (CNS) is represented by glial cells, mainly
astrocytes, which also synthesise and secrete apolipopro-
teins, in particular apolipoprotein E (ApoE), the major
apolipoprotein in the brain, thus generating cholesterol-rich
high density lipoproteins (HDLs). This cholesterol traffick-
ing, even though still poorly known, is considered to play a
key role in different aspects of neuronal plasticity and in the
stabilisation of synaptic transmission. Moreover, cell
cholesterol depletion has recently been linked to a reduction
in amyloid beta formation. Here we demonstrate that
guanosine, which we previously reported to exert several
neuroprotective effects, was able to increase cholesterol
efflux from astrocytes and C6 rat glioma cells in the
absence of exogenously added acceptors. In this effect the
phosphoinositide 3 kinase/extracellular signal-regulated
kinase 1/2 (PI3K/ERK1/2) pathway seems to play a pivotal
role. Guanosine was also able to increase the expression of
ApoE in astrocytes, whereas it did not modify the levels of
ATP-binding cassette protein A1 (ABCA1), considered the
main cholesterol transporter in the CNS. Given the
emerging role of cholesterol balance in neuronal repair,
these effects provide evidence for a role of guanosine as a
potential pharmacological tool in the modulation of
cholesterol homeostasis in the brain.
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Introduction
Although cholesterol metabolism in peripheral cells has
been studied in detail, much less is known about lipid
homeostasis in the central nervous system (CNS). There is
increasing evidence that cholesterol plays a key role in the
regulation of synaptic physiology and neurotransmission, as
well as in those mechanisms underlying synaptic plasticity
[1]. Recent data demonstrate that, in purified cultures of
retinal ganglion cells, cholesterol is able to induce the
development of new synapses [2] and that cholesterol
perturbation in neuronal lipid microdomains in presynaptic
membranes alters the clustering of calcium channel sub-
types with molecules of the exocytotic machinery, thus
impairing neurotransmitter release [3]. In addition, lipid
efflux and the consequent reduction in intracellular choles-
terol levels seem to be an important factor in amyloid
precursor protein (APP) processing. Low cellular choles-
terol concentrations favour the activity of the proteolytic
pathway of α-secretases [4, 5] and reduce that of β-
secretases [6], resulting in a decrease of beta-amyloid (Aβ)
secretion, thus strengthening the link between cholesterol
and Alzheimer’s disease pathophysiology.
Even though most of the cholesterol in the brain is
synthesised in situ, rather than imported from the blood, it
has been proposed that, at least in adult animals, neurons
seem to depend on external cholesterol supply [7]. This
cholesterol supplement could reasonably derive from glial
cells and mainly from astrocytes, which have been reported
to synthesise approximately three-times more cholesterol
than do neuronal cells [8]. Besides their presence in the
plasma, lipoproteins are also present in the cerebrospinal
fluid (CFS), where they resemble in size and density the
high-density lipoproteins (HDLs). These lipoproteins con-
tain different combinations of apolipoproteins E, A1, A2,
A4 and/or J (ApoE, ApoA1, ApoA2, ApoA4, ApoJ) [9,
10]. ApoA1 is secreted by brain endothelial cells [11] and
in only a very small amount is imported, with ApoA2, from
the circulation [12]. Both astrocytes and microglia represent
the main sources of ApoE, which is the major apolipoprotein
present in the CNS. Glial cells have been shown to generate
ApoE-containing lipoproteins, which are rich in cholesterol,
and ApoJ-containing lipoproteins that, like the ApoA1 ones,
are poor in cholesterol. Previous studies have reported that
both ApoA1 and ApoE markedly stimulate lipid efflux from
different cell types, including astrocytes [13].
The ATP-binding cassette protein A1 (ABCA1) has been
shown to act as the major transporter that mediates
cholesterol efflux from cells to lipid-free apolipoproteins
in peripheral tissues [14]. Moreover, recent evidence has
shown that: (1) ABCA1 is involved not only in lipid efflux
but also in the secretion of ApoE in human macrophages
[15]; (2) ApoE levels are reduced in brain of ABCA1-
deficient mice [16]; (3) ABCA1 mediates cholesterol efflux
and facilitates ApoE secretion from astrocytes and micro-
glia [16], thus indicating that, in glial cells, ABCA1 may
regulate not only lipid efflux but also ApoE synthesis or
secretion.
We previously reported that primary cultures of astro-
cytes and microglia express a wide range of ATP-binding
cassette (ABC) proteins, including P-glycoprotein, multi-
drug related proteins and cystic fibrosis transmembrane
regulator able to mediate the release of adenine-based
purines at rest and much more under stimulation [17]. We
have also shown that the activation of specific purinergic
receptors, namely P2Y1 ATP metabotropic receptors and
P2X7 ATP ionotropic receptors, was able to trigger the
efflux of cysteinyl leukotrienes (CysLTs) in microglia and
astrocytes, respectively [18, 19]. Pre-treatment of glial cells
with a suitable cocktail of ABC protein inhibitors reduced
the P2Y1 and the P2X7-mediated CysLT production,
confirming that, also in astrocytes and microglia, ABC
proteins are involved in the release of CysLTs and
indicating that extracellular ATP modulates the activity of
these membrane transporters.
Astrocytes are involved in several brain functions in
physiological conditions participating in neuronal devel-
opment, synaptic plasticity, activity and control of
extracellular environment. They also actively participate
in the processes triggered by brain injuries aimed at
limiting and repairing brain damage. In these mechanisms
extracellular purines, mainly adenosine and ATP, have
been reported to play important roles [20]. Astrocytes
represent the main sources of extracellular cerebral adenine-
based purines [21, 22] and express a wide array of
purinergic receptors belonging to either metabotropic
adenosine P1 and ATP P2Y sites or ionotropic ATP P2X
receptor subtypes [22].
We previously reported that rat brain cultured astrocytes
also release guanine-based purines both at rest and under
pathological conditions such as hypoxia/hypoglycaemia
[23]; moreover, we recently provided evidence for the
presence, in both rat brain and astrocyte membranes, of a
new specific cell-surface purine binding site which recog-
nises guanosine as its naturally occurring agonist [24, 25].
Challenging astrocytes with this nucleoside causes: (1)
release of adenine-based purines [26]; (2) astrocyte prolif-
638 Purinergic Signalling (2006) 2: 637–649eration [27]; (3) synthesis and release of trophic factors [22,
28]. Cell pre-treatment with this nucleoside was also able to
protect SH-SY5Y human neuroblastoma cells and rat brain
cultured astrocytes against apoptosis induced by Aβ and
staurosporine, respectively [29, 30].
On the basis of these findings we investigated in C6 rat
glioma cells and in rat brain cultured astrocytes the
intracellular signalling pathways by which guanosine was
able to modulate the efflux of cholesterol. The possible
effect of guanosine on the expression of ApoE was also
investigated.
Materials and methods
Cell culture
Rat brain cortical astrocytes
Primary cultures of astrocytes were prepared according to
the method of Levison and McCarthy [31], with slight
modifications. Two–four-day-old postnatal Sprague Daw-
ley rats were used. After they had been decapitated, their
neocortices were collected in the usual growth medium,
high glucose Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% foetal bovine serum (FBS).
Subsequently, the tissue was washed in phosphate-buffered
saline (PBS), cut in small fragments, digested with 0.025%
trypsin/0.04% ethylenediamine tetra-acetic acid (EDTA)
solution in PBS for 20 min at 37°C and then dissociated in
0.01% DNase solution in growth medium for 10 min. The
pellet was then re-suspended in growth medium also
containing 5 mM L-leucine methyl ester to restrain micro-
glia contamination. Cells were seeded onto poly-D-lysine
(10 μg/ml) coated flasks and maintained at 37°C in a
humidified incubator under 95% air and 5% CO2. After the
first 24 h, the culture medium was renewed with an
identical medium without leucine methyl ester, and it was
then replaced every 3–4 days. On the 7th and then on the
13th day in vitro (DIV), the cells were shaken for 3 h at
80 r.p.m. on a plate shaker to minimise microglia
contamination. For bioassay, confluent primary cultures of
astrocytes at the 14th DIV were trypsinised (0.025%
trypsin/0.04% EDTA dissolved in PBS, 10–20 min, 37°C)
and re-plated at a concentration of approximately 20–
25×10
3 cells/cm
2. After seeding, cells were maintained in
the usual medium containing 5 mM leucine methyl ester
only for the first 24 h.
C6 cells
Rat C6 glioma cells were cultured in low-glucose DMEM
supplemented with 5% heat-inactivated FBS.
Cholesterol efflux
Cholesterol efflux was evaluated as described by Demeester
et al. [32], with slight modifications. To evaluate choles-
terol efflux we seeded astrocytes and C6 cells in 24-well
plates at 150,000 cells/well and 100,000 cells/well, respec-
tively. Cells were labelled by incubation for 24 h in fresh
growth medium containing 2 μCi/ml of [
3H]cholesterol
(1.48 TBq/mmol, Amersham Biosciences, Milan, Italy).
Following labelling with [
3H]cholesterol, cells were washed
and incubated for an additional 24 h in serum-free media
containing 2 mg/ml bovine serum albumin (BSA) to allow
for equilibration of [
3H]cholesterol with the intracellular
pool. After this incubation, cells were washed and treated in
serum-free media as indicated. After treatment, the media
were briefly centrifuged to remove non-adherent cells. Cells
were lysed in 0.1 N NaOH. Aliquots of medium and cell
lysates were assayed by liquid scintillation counting. We
calculated the percentage cholesterol efflux by dividing the
radioactivity in the medium by the sum of the radioactivity
in the medium and cell lysate.
RNA isolation and reverse transcriptase-polymerase
chain reaction
Total RNA was isolated from confluent cells using TRIzol
reagent (Life Technologies, Milan, Italy) according to the
manufacturer’s recommendations. The resulting RNA pellet
was washed with 70% ice-cold ethanol, air dried and re-
dissolved in 30 μl diethyl-pyrocarbonate (DEPC)-treated
water. The quantity and purity of RNA were estimated
spectrophotometrically by absorbance at 260 nm, and 5 μg
were run on formaldehyde gel to confirm the integrity of
the RNA, as indicated by the preservation of the 28 and
18S rRNA.
To remove any genomic DNA contaminants we treated
RNA samples (10 μg) with 1 U Dnase-I RNase-free (Roche,
Monza,Italy).FirststrandcDNAwassynthesisedfrom1.5 μg
oftotal RNAusingthe reverse transcriptase-polymerasechain
reaction (RT-PCR) system RETROscript (Ambion, Tex.,
USA) with random hexamers. The resultant cDNA (2 μg)
was amplified in a 100 μl reaction volume containing PCR
reaction buffer, 1.5 mM MgCl2, 0.2 mM each deoxy-dNTP,
1 μM oligonucleotide primers (MWG Biotech, Ebersberg,
Germany), 2.5 U AmpliTaq Gold DNA polymerase (Applied
Biosystems, Calif., USA). The sequences of the oligonucle-
otide primers for amplification of rat ABCA1 and rat ApoE
were the following: ABCA1 (GenBank accession number
NM_178095) forward 50-CT CGAATTATTTGGAAGG-
CAC-30 and reverse 50-TTT GGGGACTGAACATCCTCT-
30; apoE (GenBank accession number BC086581) forward
50-GGAACTGACGG TACTGATGGA-30 and reverse 50-
TCGGATGCGG TCACTCAAA-30. Conditions applied for
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denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min
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conducted without the reverse transcriptase step as a control
for genomic contamination. Amplification products were
resolved by 1.5% agarose gel electrophoresis. The identity of
the products was confirmed by cycle sequencing of the
amplified cDNA.
Northern blotting analysis
Total RNA was isolated from the cells as reported above.
Equal amounts of RNA (15 μg/lane) were fractionated on
formaldehyde denaturing 1% agarose gel and blotted
overnight onto Hybond N nylon membrane (Amersham
Pharmacia Biotech, Buckinghamshire, UK). The filter was
then UV cross-linked in UV Stratalinker 1800 (Stratagene).
The blots were pre-hybridised for at least 8 h at 42-Ci na
solution containing 50% formamide, 5× Denhardt’s solu-
tion, 0.1% sodium dodecyl sulphate (SDS) and 100 μg/ml
salmon sperm DNA. Hybridisation of cDNA probes was
performed in a buffer of the same composition containing
10
6 c.p.m./ml of radiolabelled probe. cDNAs, obtained by
extracting PCR products from agarose gel slices (Millipore,
Bedford, Mass., USA), were radiolabelled by the method of
random priming (Megaprime DNA labelling system,
Amersham Pharmacia Biotech) using [alpha
32P]-dCTP
(Amersham Pharmacia Biotech). After hybridisation, the
membranes were washed in 0.1X SSC, containing 0.1%
SDS, at 50 °C and exposed to Kodak Biomax MS
autoradiography film at −80 °C with intensifying screen
for 1 day. Subsequent to hybridisation with ApoE cDNA
probe, Northern blots were hybridised with a probe for 28S
to allow correction for the recovery of RNA in each sample.
Experiments were performed at least in triplicate. For the
purpose of quantification, autoradiograms were scanned
using laser densitometry. ApoE mRNA signals were
normalised against 28S content by determination of the
ratio of the respective optical densities.
Western blotting analysis
ABCA1
ABCA1 protein expression was evaluated as described by
Wagner et al. [33]. C6 cells and astrocytes in 100 mm
dishes were incubated for 24 h in serum-free medium to
equilibrate the cells and then treated as indicated. At the
end of the incubation times, cells were lysed at 4 °C in a
buffer consisting of 10 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1.0 mM EDTA, 1% Triton X-100, 1 mM PMSF,
5 μg/ml leupeptin, 5 μg/ml aprotinin. The cells were lysed
by subjecting them to three cycles of freezing and thawing,
followed by 5 min of microcentrifugation to remove nuclei.
An aliquot of the supernatants was processed for the
assessment of protein concentration by the Bradford
method [34]. Extracts were incubated in sodium dodecyl
sulfate gel loading buffer containing 5% β-mercaptoethanol
at room temperature for 10 min before being loaded on the
gel. Electrophoresis was performed in 12% SDS–poly-
acrylamide gel using 50 μg of total protein per lane. After
separation, proteins were transferred onto a PVDF
membrane (Bio-Rad Laboratories, Milan, Italy) using a
mini-trans-blot transfer cell (Bio-Rad Laboratories). After
blocking, membranes were incubated with specific anti-
ABCA1 antibody (Novus Biologicals, Littleton, Colo.,
USA) overnight at 4 °C and then washed and exposed to
donkey anti-rabbit HPR-conjugated secondary antibody
for 1 h at room temperature (Amersham Pharmacia
Biotech). Immunocomplexes were visualised using the
enhancing chemiluminescence (ECL) detection system
(Amersham Pharmacia Biotech). To determine the equal
loading of samples per lane, at the end of each experiment
we stripped the blots and re-probed with a rabbit anti-β
actin polyclonal antibody (Santa Cruz Biotechnology),
according to the manufacturer’s instructions.
Extracellular signal-regulated kinase 1/2
Western blot analysis was used to evaluate mitogen-
activated protein kinase (MAPK) activation in C6 cells.
Cells in 100 mm dishes were incubated for 24 h in serum-
free medium to equilibrate the cells and then treated as
indicated. At the end of the indicated incubation times, cells
were harvested at 4 °C in buffers specific to the assays
(25 mM Tris buffer, pH 7.4, containing 150 mM NaCl,
100 μM sodium orthovanadate, 1.5 mM MgCl2, 1.0 mM
EDTA, 1% NP40, 10% glycerol, 1 mM PMSF, 5 μg/ml
leupeptin, 5 μg/ml aprotinin). After sonication, samples
were centrifuged at 14,000 r.p.m. for 5 min, and an aliquot
of the supernatants was processed for the assessment of
protein concentration by the Bradford method. Samples
were diluted in SDS-bromophenol blue buffer and boiled
for 5 min before loading. Electrophoresis was performed in
12% SDS-polyacrylamide gel using 10 μg of total protein
per lane. After separation, proteins were transferred onto a
PVDF membrane (Bio-Rad Laboratories) using a mini-
trans-blot transfer cell (Bio-Rad Laboratories). After block-
ing, membranes were incubated with polyclonal primary
antibody (rabbit phospho-extracellular signal-regulated ki-
nase (ERK) 1/2 antibody, New England Biolabs, Celbio,
Milan, Italy; final dilution 1:1000) for 1 h at room tem-
perature and then repeatedly washed and exposed to
donkey anti-rabbit HPR-conjugated secondary antibody
for 1 h at room temperature (Amersham Pharmacia Biotech;
final dilution 1:5000). Immunocomplexes were visualised
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Biotech). To determine the equal loading of samples per
lane, at the end of each experiment we stripped the blots
and re-probed with a goat polyclonal antibody against total
ERK1/2, followed by a secondary antibody anti-goat IgG-
HRP (both antibodies from Santa Cruz Biotechnology),
according to the manufacturer’s instructions.
ApoE
ApoE expression was evaluated as described by Mori et al.
[35]. Cells were scraped, lysed in a buffer containing
20 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 100 mM NaCl, 1%
NP40, 1 mM PMSF, 5 μg/ml leupeptin, 5 μg/ml aprotinin
(all protease inhibitors were from Sigma) and centrifuged at
14,000 r.p.m. for 10 min to remove nuclei. Cell lysate
samples were analysed for apoE expression by Western
blot. Electrophoresis was performed in 12% SDS-poly-
acrylamide gel using 50 μg of total protein per lane. After
separation, proteins were transferred onto a PVDF mem-
brane (Bio-Rad Laboratories) using a mini-trans-blot
transfer cell (Bio-Rad Laboratories). After blocking, mem-
branes were incubated with specific monoclonal anti-ApoE
antibody (BD Biosciences) overnight at 4 °C and then
washed and exposed to sheep anti-mouse HPR-conjugated
secondary antibody for 1 h at room temperature (Amersham
Pharmacia Biotech). Immunocomplexes were visualised
using the ECL detection system (Amersham Pharmacia
Biotech). To determine the equal loading of samples per
lane, at the end of each experiment we stripped the blots
and re-probed with a rabbit anti-β actin polyclonal antibody
(Santa Cruz Biotechnology), according to the manufac-
turer’s instructions.
Statistical analysis
The statistical significance was established by the analysis
of data by Student’s two-tailed t-test, using the Prism
(version 3.03) program (GraphPad Software, San Diego,
Calif., USA) with P < 0.05 considered to be significant.
Results
ATP-binding cassette protein A1 expression in primary
astrocytes of rat brain and C6 rat glioma cells
I tw a sr e p o r t e dt h a ta s t r o c y t e se x p r e s sA B C A 1[ 36],
whereas no data have been published on the expression of
this cholesterol transporter in C6 rat glioma cells. As shown
in Figure 1, RT-PCR performed by using total RNA from
cultures of rat brain astrocytes confirmed the presence of
ABCA1 in these cells. Like astrocytes (Figure 1a), C6 cells
also expressed ABCA1 mRNA. The PCR product was
separated on a 1.5% agarose gel, and a single band of
331 bp, corresponding to ABCA1 mRNA, was revealed.
The ABCA1 expression was also detected at protein
level by Western blotting in both glial cell types
(Figure 1b).
Effect of apolipoprotein A1, 22R-hydroxycholesterol
and 9-cis-retinoic acid on cholesterol efflux from primary
astrocytes of rat brain and C6 rat glioma cells
Recent studies have shown that ApoA1 is able to facilitate
cholesterol efflux from astrocytes [16, 36]. The increase of
cholesterol efflux was greater in the presence of 22R-
hydroxycholesterol (22R) and 9-cis-retinoic acid (RA),
which are ligands for the nuclear hormone liver X receptors
(LXRs) and retinoic receptors (RXRs), respectively [36].
Thus, we next examined cholesterol efflux in both
astrocytes and C6 cells either in basal conditions or under
cell treatment with the above-mentioned pharmacological
agents. To induce cholesterol efflux we added 15 μg/ml
ApoA1 to the cell medium alone or in combination with
10 μM 22R plus 10 μM RA. At the chosen times
cholesterol efflux was determined as described in Materials
and methods. As shown in Figure 2a, in astrocytes, as
expected, cholesterol efflux to ApoA1 was significantly
increased after 12 h of treatment up to 24 h. Interestingly,
the same trend was found in C6 cells (Figure 2b). In both
cell types the lipid efflux to extracellular ApoA1 was
Figure 1 Expression of ABCA1 in rat brain cultured astrocytes and
C6 rat glioma cells was investigated by RT-PCR and by Western blot.
(a) Total RNA was isolated from the cells, and 2.5 μg was used for
reverse transcription and then subjected to PCR amplification using
primer pairs specific for this transporter. Amplification products of the
expected size (331 bp) were resolved by agarose (1.5%) gel
electrophoresis. M represents the size markers as indicated; lane 1
astrocytes, lane 2 C6 cells. (b) Total proteins were isolated from the
cells, and equal amounts (50 μg) were separated on 12% SDS-
polyacrylamide gel. ABCA1 protein was detected using a rabbit
polyclonal anti-ABCA1 antibody. The immunoblot was also stripped,
and western blotting with β actin antibody was used as a loading
control. Lane 1 astrocytes; lane 2 C6 cells. Results are representative
of experiments carried out with RNA and protein isolated from at least
three independent cell culture seedings
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oxysterol plus the RXR ligand (Figure 2). Thus, as a first
step, we chose to use C6 cells to test the effect of guanosine
on cholesterol efflux.
Effect of guanosine on cholesterol efflux from C6 rat
glioma cells and primary astrocytes of rat brain
When added to the culture medium in the absence of
ApoA1, guanosine (300 μM), used at a concentration
reported to stimulate astrocyte proliferation to the maxi-
mum [27] and protect astrocytes against Aβ or staurospor-
ine-induced apoptosis [29, 30], was able to increase
significantly the cholesterol efflux from C6 cells. Interest-
ingly, the effect of this nucleoside became evident much
earlier than that obtained by treating the cells with ApoA1
in the presence or in the absence of 22R plus RA. Indeed,
as shown in Figure 3, guanosine had already markedly
increased cholesterol efflux after 1 h of treatment (approx-
imately 4.5-times the control value). The effect was still
evident after 6 h (about 1.5-times the control values),
whereas, after 18 h, guanosine-induced cholesterol efflux
was only slightly greater than the control values.
Thus, the 1 h treatment was chosen to test different
guanosine concentrations on cholesterol efflux, not only
from C6 but also from cultured astrocytes. The addition of
guanosine, up to 300 μM for 1 h, to the cell medium caused
a concentration-dependent increase in cholesterol efflux
(Figure 4) in both astrocytes and C6 cells. The calculated
EC50 for guanosine in these experiments was 38 μM and
35 μM for C6 cells and astrocytes, respectively. A
concentration of 150 μM guanosine was then chosen for
the further experiments.
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Figure 3 Time course of cholesterol efflux from C6 rat glioma cells in
both basal conditions and after treatment with 300 μM guanosine.
Cells were loaded for 24 h with [
3H]cholesterol (2 μCi/ml), incubated
for 24 h with 2 mg/ml BSA and treated with guanosine (300 μM) for
the indicated periods. Radioactivity was evaluated in both media and
cell lysates. Cholesterol efflux, expressed as a percentage, was
calculated as reported in Materials and methods. Data points were
measured in triplicate and represent the mean ± SEM of four
independent experiments. *P < 0.05, **P < 0.005, ***P < 0.0005
versus untreated cells (Student’s t-test)
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Figure 2 Time course of apolipoprotein-dependent cholesterol efflux
in rat brain cultured astrocytes (a) and C6 cells (b) treated with LXR/
RXR ligands. Cells were loaded for 24 h with [
3H]cholesterol (2 μCi/
ml), allowed to equilibrate for 24 h with 2 mg/ml BSA, and treated
with ApoA1 (15 μg/ml) in the presence or absence of 22R+RA
(10 μM each). Media and cell lysates were subjected to liquid
scintillation counting. Cholesterol efflux, expressed as a percentage,
was calculated as reported in Materials and methods. Data points were
measured in triplicate and represent the mean ± SEM of three
independent experiments. *P < 0.05, **P < 0.005 versus control
(Student’s t-test)
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Figure 4 Dose-dependent increase of cholesterol efflux induced by
guanosine in rat brain cultured astrocytes and C6 rat glioma cells.
Following labelling and equilibration, cells were incubated with the
indicated concentrations of guanosine. After 1 h, radioactivity in the
media and in the cell lysates was measured and cholesterol efflux
calculated, as reported in Materials and methods. Data points were
measured in triplicate and represent the mean ± SEM of four
independent experiments
642 Purinergic Signalling (2006) 2: 637–649Extracellular signal-regulated kinase signalling involvement
in guanosine-mediated increase of cholesterol efflux
We recently reported that guanosine induces a rapid and
time-dependent increase in ERK1/2 phosphorylation in
both microglia and astrocytes [37]. The same effect was
also described in PC12 cells [38]. Thus, we investigated
whether treatment of C6 cells with guanosine could affect
this intracellular target. As shown in Figure 5a, the
exposure of C6 cells to 150 μM guanosine caused an
increase in ERK1/2 phosphorylation as early as 5 min after
treatment, being maximal by 10 min following the
nucleoside addition and declining towards the basal values
after 20 min of treatment. Again, the effect of this
nucleoside was very similar to that obtained using cultured
astrocytes (Figure 5b). To test whether this pathway was
involved in the guanosine-mediated increase in cholesterol
efflux, we pre-treated C6 cells and astrocytes for 30 min
with the extracellular signal-regulated kinase kinase 1/2
(MEK1/2) inhibitor PD98059 (30 μM). The concentration
used was that reported to reduce: (1) the anti-apoptotic
effect of guanosine in cultured astrocytes [30]; (2) the
guanosine-induced P2Y2 up-regulation (P. Ballerini, per-
sonal communication). This drug reduced the guanosine-
mediated cholesterol efflux by approximately 60% in both
C6 cells and astrocytes (Figure 6), suggesting that the
activation of the MAPK pathway was involved in this
mechanism.
Protein kinase C and protein kinase A involvement
in guanosine-mediated increase of cholesterol efflux
It has been recently reported that, in other cell types, protein
kinase C (PKC) signalling can cause phosphorylation/
activation of ERK [39, 40]. Cell pre-treatment with
calphostin C (100 nM), at a concentration known to spe-
cifically inhibit PKCs, reduced, by approximately 35%, the
guanosine-mediated increase of cholesterol efflux in both
C6 cells and cultured astrocytes, as shown in Figure 7.
Previously, we had shown that guanosine induced a
dose-dependent increase in intracellular cyclic AMP levels
(cAMP) in slices from rat brain [25] and in rat brain
cultured astrocytes (P. Patricelli, oral communication). As
seen in Figure 7, cell pre-treatment with the specific protein
kinase A (PKA) inhibitor KT5020 for 3 h reduced only by
approximately 30% the guanosine effect on cholesterol
efflux from C6 cells and astrocytes.
Phosphoinositide 3 kinase involvement
in guanosine-mediated increase of cholesterol efflux
We have recently shown that another intracellular pathway
activated by guanosine is represented by phosphoinositide 3
Figure 5 Time-dependent increase of ERK1/2 phosphorylation
induced by guanosine in rat brain cultured C6 rat glioma cells
(a) and astrocytes (b). Cells were serum deprived for 24 h and
then treated for the indicated periods with 150 μM guanosine.
Cell lysates were prepared as described in Materials and methods
and immunoblotted with phospho-ERK specific antibodies. After
development, the membranes were stripped and re-probed with
regular antibody against ERK1/2. The blots are representative of at
least three independent experiments with similar results. Immunoblots
were quantified by densitometric analysis, and the ERK1/2 values,
normalised to the corresponding β actin values, are expressed as
number of times of increase versus basal values (untreated cells) in
the histograms under the blots. Data are mean ± SEM of three
independent experiments. *P < 0.05, **P < 0.005, ***P < 0.0005
versus basal values (Student’s t-test)
Purinergic Signalling (2006) 2: 637–649 643kinase (PI3K) [30]. Thus, we investigated whether this
transduction signalling was involved in guanosine-mediated
increase of cholesterol efflux. To this aim, we used the cell-
permeable selective PI3K inhibitor, LY294002. When C6
cells and astrocytes were pre-treated for 30 min with
LY294002 (30 μM), the increase in cholesterol efflux
induced by guanosine proved to be significantly reduced by
approximately 50%, as shown in Figure 8. When the drug
was used in combination with the MEK1/2 inhibitor
PD98059, the effect was similar to that obtained by
LY294002 (Figure 8) and PD98059 (Figure 6) given alone.
Effect of apolipoprotein A1, 22R-hydroxycholesterol,
9-cis-retinoic acid and guanosine on ATP-binding
cassette A1 expression in C6 rat glioma cells
and primary astrocytes of rat brain
Very little is known of the pharmacological regulation of
cholesterol efflux mechanisms, not only in the CNS but also
in peripheral tissues. Evidence has been provided on the
capability of ApoA1, oxysterols and RA in causing an
increase of ABCA1 expression, both at message level and
protein level in different cell types, including neuronal cells
[36, 41]. To determine whether the induction of ABCA1
might be involved in the enhanced efflux of cholesterol
induced by the guanine-based nucleoside, we exposed the
cells to 150 μM guanosine for 1 h, 3 h and 6 h (Figure 9).
As shown by the representative Western blot reported in
Figure 9, guanosine was unable to modify ABCA1
expression either in C6 glioma cells or in rat brain
astrocytes at the chosen times. On the other hand, the
combination of ApoA1, 22R and RA, considered as
positive control, significantly increased the protein levels
in both types of glial cells after 12 h of treatment, a time
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Figure 8 Effect of the PI3K inhibitor LY294002 alone or in
combination with the MEK1/2 inhibitor PD98059 on cholesterol
efflux induced by guanosine. Following labelling and equilibration,
cells were pre-incubated for 30 min with LY294002 (30 μM) or with
LY294002 (30 μM) plus PD98059 (30 μM) and then treated with
150 μM guanosine. After 1 h the radioactivity in media and cell
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##P <
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terol efflux could be pointed out.
Effect of guanosine on apolipoprotein E expression
in primary astrocytes of rat brain
Recent studies in other cell types, such as human macro-
phages, have indicated that the removal of secreted ApoE
from the medium by the addition of specific antibodies
significantly reduced cholesterol efflux from these cells
[41]. We then tested whether guanosine would be able to
increase ApoE expression in glial cells after 1 h of incu-
bation, a time at which the nucleoside was able to increase
cholesterol efflux to the maximum.
As shown by the representative Northern blot reported in
Figure 10a, 150 μM guanosine induced ApoE expression in
astrocytes. This increase was paralleled by a rise in ApoE
content in these cells, measured by Western blot analysis as
reported in Figure 10b.
Discussion
There is increasing evidence indicating that cholesterol
trafficking can have important implications in CNS func-
tion, both in physiological and even more in pathological
conditions; however, the mechanisms underlying the
synthesis, release, redistribution and uptake of cholesterol
among the cells in the CNS are still poorly known.
It has been reported that the efflux of cholesterol
complexed to lipoproteins containing ApoE from glial cells
promotes synapse development in cultured neurons [42].
These data are in agreement with results showing that most
synapses in the CNS develop after the differentiation of
astrocytes [43].
The role of cholesterol homeostasis has also been
pointed out by data demonstrating that ABCA1 and ApoE
are markedly up-regulated at sites of brain damage, thus
strongly suggesting a role in neuronal repair for molecules
that participate in cholesterol efflux and redistribution [44].
Additionally, ABCA1, recognised as an essential protein
for cholesterol secretion and subsequent HDL formation,
facilitates cholesterol efflux to exogenous apolipoproteins
in primary cultures of glial cells, including astrocytes [16].
The results reported in the present paper confirm that
treatment of astrocytes with the lipid acceptor ApoA1
increases cholesterol efflux in a time-dependent manner.
The increase of cholesterol efflux was greater when the
combination of the natural and synthetic LXR/RXR ligands
was added to the medium of astrocytes pre-treated with
ApoA1. In agreement with data already reported in the
literature, our results show that the combination of ApoA1,
22R and RAwas able to cause, in these cells, an increase in
Figure 9 Time course of ABCA1 expression induced by 150 μM
guanosine in (a) C6 rat glioma cells and (b) rat brain cultured
astrocytes. Cells were serum deprived for 24 h and were treated for
the indicated periods with 150 μM guanosine or with ApoA1
(15 μg/ml) plus 22R (10 μg/ml) and RA (10 μg/ml). Fifty
microgrammes of total protein were loaded per lane and immuno-
blotted with rabbit polyclonal antibody to ABCA1. Western blotting
with β actin antibody was used as a loading control. The blots are
representative of three independent experiments with similar results.
Immunoblots were quantified by densitometric analysis, and the
ABCA1 values, normalised to the corresponding β actin values, are
expressed as number of times of increase versus basal values
(untreated cells) in the histograms under the blots. Data are
mean ± SEM of three independent experiments. *P < 0.05 versus
basal values (Student’s t-test)
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using C6 cells, indicating that these rat glioma cells can
represent a good model to study cholesterol efflux and its
possible modulation in glia.
Besides being the main source of cholesterol, astrocytes
are also recognised as the major source of extracellular
purines, both adenine and guanine-based ones, in the CNS
[21, 23]. Interestingly, it has also been shown that the
extracellular concentration of guanine-based purines is
dramatically enhanced, following insults, more than that
of the adenine-based counterparts [23]. Even though the
role exerted by adenosine and ATP in the CNS is known
much better than that played by guanosine, a great body of
evidence is accumulating on the neuroprotective effects
mediated by this nucleoside.
In this view, we previously reported that, in astrocytes,
guanosine was able to: (1) promote cell proliferation [27,
45]; (2) induce the synthesis and release of neurotrophic
and pleiotrophic factors [23, 37, 46, 47]; (3) protect the
cells against Aβ- or staurosporine-induced apoptosis [29,
30]. Guanosine is also able to modulate neurotransmission
by stimulating glutamate uptake in astrocytes [48].
Moreover, this nucleoside has been shown to be
effective in vivo, being able to produce anti-convulsant
action against seizures caused by glutamatergic agents [49],
inhibit locomotor stimulation induced by dizocilpine [50]
and promote remyelination and functional recovery in rats
submitted to spinal cord injury [51].
Recently, we reported evidence for the presence of a
high-affinity binding site for guanosine in membranes from
whole rat brain and from astrocytes [24, 25]. Thus, at least
some of the effects mediated by extracellular guanosine
may be exerted by its binding to these specific cell
membrane sites. Our laboratories are currently investigating
the structure and signal transduction pathways of this
potential new purinergic receptor.
In the present study we show that guanosine enhances
cholesterol efflux from both C6 cells and rat brain cultured
astrocytes 1 h after treatment in a dose-dependent manner.
The increase in cholesterol efflux was still evident 6 h after
treatment, though to a lesser extent. The decrease of the
guanosine effect could fit well with our previous observa-
tions showing that guanosine, added to the astrocyte culture
medium, was metabolised by 75% within 2–3h[ 26].
RFigure 10 Modulation of ApoE expression by ApoA1 plus LXR/
RXR ligands and guanosine in rat brain cultured astrocytes by
Northern blot (a) and Western blot (b). Cells were treated for 12 h
with a combination of 15 μg/ml ApoA1, 10 μM 22R and 10 μMR A
or for 1 h with 150 μM guanosine. At the end of the periods of
treatment (a) total RNA was isolated as described in Materials and
methods and equal amounts were electrophoresed through formalde-
hyde-containing gel, transferred to Nylon membrane and hybridised
with
32P-labelled cDNA probes. 28S probe was used as control for
loading and integrity of the RNAs. The blot is representative of at
least three independent experiments. Values from densitometric
analysis were normalised to those of 28S and expressed as number
of times of increase versus basal values (untreated cells) in the
histograms under the blot. Data are mean ± SEM of three
independent experiments. *P < 0.05, **P < 0.005 versus basal values
(Student’s t-test). (b) ApoE levels in whole cell lysates were
determined using a monoclonal anti-ApoE antibody. β actin was used
as loading control. Immunoblots were quantified by densitometric
analysis and the ApoE values, normalised to the corresponding β actin
values, are expressed as number of times of increase versus basal
values (untreated cells) in the histograms under the blots. Data are
mean ± SEM of three independent experiments. *P < 0.05, **P <
0.005 versus basal values (Student’s t-test)
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in the modulation of cholesterol efflux in different cell types.
We have already reported that ERK1/2 phosphorylation
is an important event involved in several guanosine-
mediated effects in astrocytes, including the synthesis of
trophic factors and the protection against staurosporine-
induced apoptosis [30, 47]. Recently, this intracellular
pathway has also been shown to be involved in the
guanosine-mediated protection of neuronal cells from
chemical hypoxia [38].
In the present study we report that, as expected,
guanosine also significantly and rapidly triggered ERK1/2
phosphorylation in C6 rat glioma cells. Moreover, this
pathway also seems to play an important role in mediating
the effect of guanosine on cholesterol efflux from glial
cells, as shown by the inhibitory action exerted by the
MEK1/2 inhibitor PD98059.
Another intracellular pathway activated by guanosine,
when added to the astrocyte culture medium, is represented
by PI3K. We have shown that the staurosporine-mediated
pro-apoptotic effect was markedly and dose-dependently
reduced in cells pre-treated with guanosine [30]. The
protective effect of the nucleoside was abolished when
astrocytes were pre-incubated with LY294002 (30 μM), a
selective inhibitor of PI3K [30]. Consistent with these
findings, our results obtained using the same inhibitor
suggest that the PI3K pathway could represent a key
mediator that links the activation of a potential guanosine
purinoceptor to the modulation of mechanisms underlying
cholesterol efflux in glial cells. Since the cell treatment with
the combination of LY294002 and PD98059 caused a
reduction in guanosine-induced cholesterol efflux, which
was similar to that obtained by each drug added alone to
culture medium, it is tempting to speculate that the two
pathways converge. Thus, the PI3K/ERK1/2 pathway may
represent a signalling event involved in the guanosine-
mediated regulation of cholesterol efflux in glial cells.
A number of protein kinases have been reported to
modulate the activity of ABCA1, thus influencing choles-
terol efflux in different cell types [14]. In kidney cells,
RAW mouse macrophages and in a Flip-in 293 cell line, it
has been shown that PKA-mediated phosphorylation of
ABCA1 is required for its lipid transport activity [52].
It has also been reported that PKC activators stimulate
cholesterol efflux and PKC inhibitors substantially reduce
cholesterol efflux induced by ApoA1 in macrophages and
human THP-1 cells [53].
Previously, we observed that, in slices of rat cerebral
cortex, guanosine caused an increase in intracellular cAMP
accumulation [25]. Guanosine-induced rise in cAMP levels
could also be detected in rat brain cultured astrocytes,
though to a lesser extent (P. Patricelli, personal communi-
cation). Our results show that the PKA inhibitor reduced,
by approximately 30%, guanosine-mediated cholesterol
efflux in both C6 rat glioma cells and cultured astrocytes.
Similar results were obtained by pre-treating glial cells with
the PKC inhibitor, thus suggesting that these kinases can
participate in the guanosine-mediated modulation of cho-
lesterol efflux in these cells.
Data regarding the possible pharmacological modulation
of ABCA1 in the CNS are still limited. It has been reported
that the increased cholesterol efflux induced by ApoA1 plus
22R and RA in astrocytes correlates with an induced
ABCA1 mRNA expression in these cells [36]. Accordingly,
our results show that the LXR/RXR ligands in combination
with ApoA1, considered as reference drugs, increased the
levels of ABCA1 protein in both C6 cells and rat brain
cultured astrocytes.
On the other hand, guanosine, used at the same con-
centration and times that were able to trigger an increased
cholesterol efflux from the cells, was unable to induce an
up-regulation of the lipid membrane transporter, suggesting
that this mechanism seems not to be involved in the
nucleoside-mediated effect.
Interestingly, we observed that guanosine was able to
enhance cholesterol efflux without the addition of apolipo-
proteins to the culture medium. It has been reported that
ABCA1 is a peculiar ABC protein in that it is necessary
that apolipoproteins bind either directly to the transporter or
indirectly, possibly through the stimulation of other
receptors present on the plasma membrane, to activate
ABCA1-mediated lipid efflux [54]. Apolipoproteins could
also stimulate ABCA1-mediated lipid efflux by favouring
the intracellular recycling of this ABC protein. However,
since astrocytes are considered to be, together with micro-
glial cells, the main source of ApoE in the CNS, it could be
speculated that guanosine was able to enhance the
expression of this apolipoprotein. This event could make
the addition of exogenous apolipoproteins less critical to
trigger an ABCA1-dependent cholesterol efflux. This
hypothesis seems to be likely; indeed, we found that
guanosine had already increased the expression of ApoE
in rat brain cultured astrocytes both at mRNA level and at
protein level after 1 h treatment when the nucleoside
stimulated the lipid efflux.
Further experiments are needed to evaluate better the
functional role of ABCA1 and that of other elements, such
as the enzymes responsible for cholesterol metabolism, in
guanosine-mediated efflux of cholesterol.
However, on the whole, the results presented here
strongly suggest that guanosine could have a role in
ameliorating the delivery of cholesterol from glial cells,
thus potentially favouring neuronal repair and regeneration.
This event could be considered a further mechanism by
which this guanine-based nucleoside, regulating astrocyte
activity, may exert its neuroprotective effects.
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